These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

226 related items for PubMed ID: 26457546

  • 1. Adjuvant imatinib treatment in gastrointestinal stromal tumor: which risk stratification criteria and for how long? A case report.
    Blay JY, Levard A.
    Anticancer Drugs; 2016 Jan; 27(1):71-5. PubMed ID: 26457546
    [Abstract] [Full Text] [Related]

  • 2. Efficacy and Tolerability of 5-Year Adjuvant Imatinib Treatment for Patients With Resected Intermediate- or High-Risk Primary Gastrointestinal Stromal Tumor: The PERSIST-5 Clinical Trial.
    Raut CP, Espat NJ, Maki RG, Araujo DM, Trent J, Williams TF, Purkayastha DD, DeMatteo RP.
    JAMA Oncol; 2018 Dec 01; 4(12):e184060. PubMed ID: 30383140
    [Abstract] [Full Text] [Related]

  • 3. Retrospective analysis of 85 cases of intermediate-risk gastrointestinal stromal tumor.
    Fu Y, Hao H, Guo L, Yang G, Zhang X.
    Oncotarget; 2017 Feb 07; 8(6):10136-10144. PubMed ID: 28052037
    [Abstract] [Full Text] [Related]

  • 4. [Efficacy observation on imatinib reintroduction in gastrointestinal stromal tumor with high recurrence risk after imatinib adjuvant therapy failure].
    Dong Z, Gao J, Gong J, Li J, Li Y, Wang X, Li Y, Shen L, Li J.
    Zhonghua Wei Chang Wai Ke Za Zhi; 2016 Nov 25; 19(11):1286-1289. PubMed ID: 27928801
    [Abstract] [Full Text] [Related]

  • 5. Two-year adjuvant imatinib mesylate after complete resection of localized, high-risk GIST with KIT exon 11 mutation.
    Kang YK, Kang BW, Im SA, Lee JL, Park SR, Kang WK, Chang HM, Kim TW, Oh DY, Jung KH, Ryu MH.
    Cancer Chemother Pharmacol; 2013 Jan 25; 71(1):43-51. PubMed ID: 23053257
    [Abstract] [Full Text] [Related]

  • 6. Is 3-years duration of adjuvant imatinib mesylate treatment sufficient for patients with high-risk gastrointestinal stromal tumor? A study based on long-term follow-up.
    Lin JX, Chen QF, Zheng CH, Li P, Xie JW, Wang JB, Lu J, Chen QY, Cao LL, Lin M, Tu RH, Huang CM.
    J Cancer Res Clin Oncol; 2017 Apr 25; 143(4):727-734. PubMed ID: 28083710
    [Abstract] [Full Text] [Related]

  • 7. Time to Definitive Failure to the First Tyrosine Kinase Inhibitor in Localized GI Stromal Tumors Treated With Imatinib As an Adjuvant: A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Intergroup Randomized Trial in Collaboration With the Australasian Gastro-Intestinal Trials Group, UNICANCER, French Sarcoma Group, Italian Sarcoma Group, and Spanish Group for Research on Sarcomas.
    Casali PG, Le Cesne A, Poveda Velasco A, Kotasek D, Rutkowski P, Hohenberger P, Fumagalli E, Judson IR, Italiano A, Gelderblom H, Adenis A, Hartmann JT, Duffaud F, Goldstein D, Broto JM, Gronchi A, Dei Tos AP, Marréaud S, van der Graaf WT, Zalcberg JR, Litière S, Blay JY.
    J Clin Oncol; 2015 Dec 20; 33(36):4276-83. PubMed ID: 26573069
    [Abstract] [Full Text] [Related]

  • 8. The economic burden of gastrointestinal stromal tumor (GIST) recurrence in patients who have received adjuvant imatinib therapy.
    Guerin A, Sasane M, Gauthier G, Keir CH, Zhdavana M, Wu EQ.
    J Med Econ; 2015 Mar 20; 18(3):241-8. PubMed ID: 25422992
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. [Efficacy observation on imatinib adjuvant therapy with longer duration in patients with gastrointestinal stromal at intermediate or high risk of recurrence].
    Li J, Dang YZ, Gao J, Shen L.
    Zhonghua Wei Chang Wai Ke Za Zhi; 2013 Mar 20; 16(3):216-20. PubMed ID: 23536338
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Cost-effectiveness of 3-year vs 1-year adjuvant therapy with imatinib in patients with high risk of gastrointestinal stromal tumour recurrence in the Netherlands; a modelling study alongside the SSGXVIII/AIO trial.
    Majer IM, Gelderblom H, van den Hout WB, Gray E, Verheggen BG.
    J Med Econ; 2013 Sep 20; 16(9):1106-19. PubMed ID: 23808902
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Expression of cell cycle regulators and frequency of TP53 mutations in high risk gastrointestinal stromal tumors prior to adjuvant imatinib treatment.
    Ihle MA, Huss S, Jeske W, Hartmann W, Merkelbach-Bruse S, Schildhaus HU, Büttner R, Sihto H, Sundby Hall K, Eriksson M, Reichardt P, Joensuu H, Wardelmann E.
    PLoS One; 2018 Sep 20; 13(2):e0193048. PubMed ID: 29451912
    [Abstract] [Full Text] [Related]

  • 15. Preoperative imatinib mesylate (IM) for huge gastrointestinal stromal tumors (GIST).
    Tang S, Yin Y, Shen C, Chen J, Yin X, Zhang B, Yao Y, Yang J, Chen Z.
    World J Surg Oncol; 2017 Apr 11; 15(1):79. PubMed ID: 28399894
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Adjuvant imatinib in high-risk resected gastrointestinal stromal tumors: Merely delaying the inevitable?
    Sutton TL, Billingsley KG, Johnson AJ, Corless CL, Blanke CD, Heinrich MC, Mayo SC.
    J Surg Oncol; 2024 Jul 11; 130(1):40-46. PubMed ID: 38924626
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Deciding on the duration of adjuvant therapy in gastrointestinal stromal tumor.
    Whooley P, Correa E, von Mehren M.
    Expert Rev Anticancer Ther; 2021 May 11; 21(5):547-556. PubMed ID: 33353442
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.